Home / OMER : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does OMER make money? Does OMER have pricing power? What's the Earnings Whisper? Will OMER profit more as the business scales? What is OMER's management track record? Is OMER's current price justified?

Omeros Corporation

$18.28 +$1.90 (+11.60%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$18.59

Day Range

$18.28$18.98

Year Range

$3.94$19.65

Market Cap

1.32B

AVG Volume

1.93M

Trailing/Forward PE

9.57/18.28

PEG ratio

0.77

Dividend Yield

Next Earnings Date

2026-11-12

Primary Exchange

NASDAQ

Revenue (USD)

OMER Revenue (USD) by year
Period	Revenue (USD)
2025	0
2024	0
2023	0
2022	0
2021	-79.89M
2020	73.81M
2019	111.8M
2018	29.87M
2017	64.83M
2016	41.62M

Net Income (USD)

OMER Net Income (USD) by year
Period	Net Income (USD)
2025	-3.35M
2024	-156.81M
2023	-117.81M
2022	47.42M
2021	194.24M
2020	-138.06M
2019	-84.49M
2018	-126.76M
2017	-53.48M
2016	-66.75M

Operating Income (USD)

OMER Operating Income (USD) by year
Period	Operating Income (USD)
2025	-122.8M
2024	-169.26M
2023	-164.53M
2022	-163.39M
2021	-231.46M
2020	-110.6M
2019	-63.38M
2018	-112.22M
2017	-43.9M
2016	-54.28M

EBITDA (USD)

OMER EBITDA (USD) by year
Period	EBITDA (USD)
2025	1.84M
2024	-157M
2023	-143.16M
2022	-158.37M
2021	-228.31M
2020	-121.7M
2019	-60.06M
2018	-122.47M
2017	-41.9M
2016	-59.09M

Cash Flows (USD)

OMER Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-116.16M
2024	-148.97M
2023	74.3M
2022	-86.6M
2021	-110M
2020	-100.37M
2019	-60.41M
2018	-104.3M
2017	-36.58M
2016	-51.63M

EPS (USD)

OMER EPS (USD) by year
Period	EPS (USD)
2025	-0.06
2024	-2.7
2023	-1.88
2022	2.09
2021	3.09
2020	-2.4
2019	-1.7
2018	-2.61
2017	-1.17
2016	-1.65

Expenses (USD)

OMER Expenses (USD) by year
Period	Expenses (USD)
2025	112.52M
2024	168.92M
2023	164.75M
2022	163.5M
2021	151.7M
2020	183.79M
2019	174.66M
2018	142.15M
2017	107.99M
2016	94.61M

Cash & Debt (USD)

OMER Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	171.8M
2024	90.13M
2023	171.85M
2022	194.92M
2021	157.27M
2020	134.95M
2019	60.79M
2018	60.5M
2017	83.75M
2016	45.33M

Debt ratios

OMER Debt ratios by year
Period	Debt ratios
2025	-0.15
2024	-0.17
2023	-0.29
2022	-0.26
2021	-0.36
2020	-0.39
2019	-0.47
2018	-0.31

Margins

OMER Margins by year
Period	Margins
2021	100.19%
2020	98.78%
2019	99.23%
2018	98.29%
2017	98.34%
2016	96.61%
2015	92.29%

Return on Capital

OMER Return on Capital by year
Period	Return on Capital
2025	2.76%
2024	85.87%
2023	471.57%
2022	55.34%
2021	816.8%
2020	114.33%
2019	77.5%
2018	-19.5%
2017	1900.53%
2016	178.24%

Shares Outstanding

OMER Shares Outstanding by year
Period	Shares Outstanding
2025	63.51M
2024	58.17M
2023	62.44M
2022	62.76M
2021	62.55M
2020	61.66M
2019	50.62M
2018	49.01M
2017	48.03M
2016	43.19M

Book Value Per Share (USD)

OMER Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	-1.91
2024	-3.14
2023	-0.4
2022	1.37
2021	0.38
2020	-1.96
2019	-2.15
2018	13.26
2017	-0.06
2016	-0.87

Total Assets (USD)

OMER Total Assets (USD) by year
Period	Total Assets (USD)
2025	325.63M
2024	277.08M
2023	378.27M
2022	590.97M
2021	419.27M
2020	181.04M
2019	136.97M
2018	95.94M
2017	116.33M
2016	67.28M

Employee Count

OMER Employee Count by year
Period	Employee Count
2025	175
2024	202
2023	198
2022	196
2021	213
2020	277
2019	64
2018	236
2017	173
2016	154

PE Ratio

OMER PE Ratio by year
Period	PE Ratio
Sep 26	10.56
Sep 26	10.95
Aug 26	10.75
Aug 26	11.14
Aug 26	9.93
Aug 26	11.06
Jul 26	9.88
Jul 26	8.17
Jul 26	8.09
Jul 26	8.58
Jul 26	7.75
Jun 26	7.24
Jun 26	8.58
Jun 26	7.29
Jun 26	8.17
May 26	9.21
May 26	9.56
May 26	10.22
Mar 24	10.85
Mar 24	10.69
Mar 24	11.48
Mar 24	13.77
Mar 24	15.03
Feb 24	12.96
Feb 24	15.38
Feb 24	12.01
Feb 24	10.69
Jan 24	10.35
Jan 24	12.23
Jan 24	11.1
Jan 24	9.62
Dec 23	10.28
Dec 23	11.42
Dec 23	8.93
Dec 23	8.08
Dec 23	7.01
Nov 23	5.79
Nov 23	5.16
Nov 23	3.93
Nov 23	2
Oct 23	1.68
Oct 23	1.92
Oct 23	3.54
Oct 23	4.32
Sep 23	4.55
Sep 23	4.59
Sep 23	4.85
Sep 23	5.26
Sep 23	5.52
Aug 23	5.94
Aug 23	5.51
Aug 23	6.71
Aug 23	5.74
Jul 23	5.86
Jul 23	7.13
Jul 23	6.94
Jul 23	7.09
Jun 23	7.31
Jun 23	7.38
Jun 23	8.03
Jun 23	10.08
Jun 23	9.96
May 23	7.77
May 23	8.42
May 23	7.68
May 23	6.78
Apr 23	7.68
Apr 23	7.49
Apr 23	8.41
Apr 23	6.34
Mar 23	6.15
Mar 23	5.11
Mar 23	4.69
Mar 23	1.03
Mar 23	1.21
Feb 23	1.19
Feb 23	1.41
Feb 23	1.59
Feb 23	0.97
Jan 23	0.85
Jan 23	0.81
Jan 23	0.91
Jan 23	0.89
Dec 22	0.71
Dec 22	0.8
Dec 22	0.56
Dec 22	0.65
Dec 22	0.65
Nov 22	0.68
Nov 22	0.81
Nov 22	0.86
Nov 22	1.04
Oct 22	1.12
Oct 22	1
Oct 22	1.1
Oct 22	1.27
Sep 22	1.02
Sep 22	1.13
Sep 22	1.13
Sep 22	1.73

Free Cash Flow Yield

OMER Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-5.21%
Sep 26	-5.03%
Aug 26	-5.12%
Aug 26	-4.94%
Aug 26	-5.54%
Aug 26	-9.95%
Jul 26	-11.13%
Jul 26	-13.46%
Jul 26	-13.6%
Jul 26	-12.82%
Jul 26	-14.2%
Jun 26	-15.2%
Jun 26	-12.82%
Jun 26	-15.08%
Jun 26	-13.46%
May 26	-11.94%
May 26	-11.5%
May 26	-10.76%
May 26	-12.94%
May 26	-12.14%
Apr 26	-13.52%
Apr 26	-13.61%
Apr 26	-15.92%
Apr 26	-16.78%
Mar 26	-16.09%
Mar 26	-14.45%
Mar 26	-14.2%
Mar 26	-13.77%
Feb 26	-13.19%
Feb 26	-13.2%
Feb 26	-13.6%
Feb 26	-14.15%
Jan 26	-13.6%
Jan 26	-13.32%
Jan 26	-13.23%
Jan 26	-12.73%
Jan 26	-9.7%
Dec 25	-10.12%
Dec 25	-16.56%
Dec 25	-15.66%
Dec 25	-14.65%
Nov 25	-16.4%
Nov 25	-17.92%
Nov 25	-20.2%
Nov 25	-30.8%
Oct 25	-27.69%
Oct 25	-26.88%
Oct 25	-25.02%
Oct 25	-48.44%
Oct 25	-44.31%
Sep 25	-45.5%
Sep 25	-48.55%
Sep 25	-48.9%
Sep 25	-48.67%
Aug 25	-48.79%
Aug 25	-46.12%
Aug 25	-46.02%
Aug 25	-60.67%
Aug 25	-68.24%
Jul 25	-64.32%
Jul 25	-73.31%
Jul 25	-67.49%
Jul 25	-76.98%
Jun 25	-76.98%
Jun 25	-76.74%
Jun 25	-72.45%
Jun 25	-65.34%
May 25	-79.72%
May 25	-77.95%
May 25	-76.5%
May 25	-41.44%
May 25	-35.72%
Apr 25	-36.57%
Apr 25	-39.43%
Apr 25	-39.72%
Apr 25	-37.86%
Mar 25	-31.56%
Mar 25	-29.38%
Mar 25	-31.75%
Mar 25	-34.9%
Feb 25	-31.79%
Feb 25	-29.12%
Feb 25	-29.12%
Feb 25	-30.9%
Jan 25	-31.01%
Jan 25	-31.94%
Jan 25	-28.65%
Jan 25	-30.24%
Jan 25	-23.85%
Dec 24	-22.89%
Dec 24	-25.93%
Dec 24	-35.03%
Dec 24	-23.02%
Nov 24	-23.55%
Nov 24	-24.5%
Nov 24	-39.6%
Nov 24	-60.86%
Nov 24	-65.79%
Oct 24	-64.06%
Oct 24	-64.68%

Price to Sales

OMER Price to Sales by year
Period	Price to Sales
Sep 26	34.32
Sep 26	35.58
Aug 26	34.94
Aug 26	36.18
Aug 26	32.27
Aug 26	96.32
Jul 26	86.07
Jul 26	71.17
Jul 26	70.44
Jul 26	74.73
Jul 26	67.46
Jun 26	63.03
Jun 26	74.73
Jun 26	63.54
Jun 26	71.17
May 26	80.26
May 26	83.31
May 26	89.05
Mar 23	-2.56
Mar 23	-3.02
Feb 23	-2.98
Feb 23	-3.52
Feb 23	-3.97
Feb 23	-2.43
Jan 23	-2.12
Jan 23	-2.03
Jan 23	-2.28
Jan 23	-2.22
Dec 22	-1.77
Dec 22	-1.99
Dec 22	-1.41
Dec 22	-1.62
Dec 22	-1.61
Nov 22	-1.7
Nov 22	-2.03
Nov 22	-2.15
Nov 22	-2.52
Oct 22	-2.72
Oct 22	-2.43
Oct 22	-2.68
Oct 22	-3.08
Sep 22	-2.47
Sep 22	-2.75
Sep 22	-2.76
Sep 22	-4.2
Sep 22	-3.54
Aug 22	-3
Aug 22	-4.61
Aug 22	-5.6
Aug 22	-5.36
Jul 22	-3.91
Jul 22	-3.09
Jul 22	-3.18
Jul 22	-3.2
Jul 22	-3.64
Jun 22	-2.05
Jun 22	-1.57
Jun 22	-1.64
Jun 22	-1.96
May 22	-2.14
May 22	-2.21
May 22	-2.51
May 22	-2.31
Apr 22	-2.72
Apr 22	-3.22
Apr 22	-4.02
Apr 22	-4.49
Apr 22	-4.73
Mar 22	-4.85
Mar 22	-5.13
Mar 22	-4.78
Mar 22	-5
Feb 22	42.27
Feb 22	41.69
Feb 22	37.16
Feb 22	36.92
Jan 22	33.1
Jan 22	31.16
Jan 22	33.92
Jan 22	36.86
Dec 21	37.81
Dec 21	44.92
Dec 21	43.1
Dec 21	44.51
Dec 21	40.39
Nov 21	43.68
Nov 21	46.33
Nov 21	48.27
Nov 21	12.82
Oct 21	10.64
Oct 21	11.02
Oct 21	13.12
Oct 21	11.37
Oct 21	14.5
Sep 21	26.96
Sep 21	27.12
Sep 21	26.53
Sep 21	26.73
Aug 21	26.77
Aug 21	25.07

EV/EBITDA

OMER EV/EBITDA by year
Period	EV/EBITDA
Sep 26	9.33
Sep 26	9.69
Aug 26	9.51
Aug 26	9.86
Aug 26	8.75
Aug 26	12.14
Jul 26	11.05
Jul 26	9.47
Jul 26	9.39
Jul 26	9.85
Jul 26	9.07
Jun 26	8.6
Jun 26	9.85
Jun 26	8.65
Jun 26	9.47
May 26	10.43
May 26	10.76
May 26	11.37
May 26	524.88
May 26	557.02
Apr 26	504.15
Apr 26	501.04
Apr 26	433.66
Apr 26	413.28

Price/Operating Cashflow

OMER Price/Operating Cashflow by year
Period	Price/Operating Cashflow
May 24	2.93
May 24	3.12
Apr 24	2.63
Apr 24	2.55
Apr 24	3.14
Apr 24	2.87
Mar 24	2.58
Mar 24	2.54
Mar 24	2.73
Mar 24	3.27
Mar 24	3.57
Feb 24	3.08
Feb 24	3.65
Feb 24	2.85
Feb 24	2.54
Jan 24	2.46
Jan 24	2.91
Jan 24	2.64
Jan 24	2.29
Dec 23	2.44
Dec 23	2.71
Dec 23	2.12
Dec 23	1.92
Dec 23	1.67
Nov 23	1.37
Nov 23	1.22
Nov 23	0.93
Nov 23	0.89
Oct 23	0.75
Oct 23	0.86
Oct 23	1.58
Oct 23	1.93
Sep 23	2.03
Sep 23	2.04
Sep 23	2.16
Sep 23	2.34
Sep 23	2.46
Aug 23	2.65
Aug 23	2.45
Aug 23	2.99
Aug 23	2.6
Jul 23	2.65
Jul 23	3.23
Jul 23	3.14
Jul 23	3.21
Jun 23	3.31
Jun 23	3.34
Jun 23	3.63
Jun 23	4.56
Jun 23	4.51
May 23	3.52
May 23	3.81
May 23	3.47

Price to Book

OMER Price to Book by year
Period	Price to Book
Nov 23	3.92
Oct 23	3.31
Oct 23	3.77
Oct 23	6.95
Oct 23	8.49
Sep 23	8.95
Sep 23	9.01
Sep 23	9.53
Sep 23	10.32
Sep 23	10.85
Aug 23	11.67
Aug 23	10.81
Aug 23	13.17
Aug 23	4.88
Jul 23	4.99
Jul 23	6.06
Jul 23	5.9
Jul 23	6.03
Jun 23	6.22
Jun 23	6.28
Jun 23	6.83
Jun 23	8.58
Jun 23	8.47
May 23	6.61
May 23	7.16
May 23	6.53
May 23	3.75
Apr 23	4.25
Apr 23	4.15
Apr 23	4.65
Apr 23	3.51
Mar 23	3.41
Mar 23	2.83
Mar 23	2.59
May 22	7.76
Apr 22	9.13
Apr 22	10.81
Apr 22	13.52
Apr 22	15.1
Apr 22	15.89
Mar 22	16.31
Mar 22	17.23
Mar 22	16.05
Mar 22	16.81
May 19	1.48
Apr 19	1.42
Apr 19	1.4
Apr 19	1.39
Apr 19	1.4
Mar 19	1.31
Mar 19	1.27
Mar 19	1.21
Mar 19	1.19
Mar 19	1.14
Feb 18	50.22
Feb 18	55.3
Feb 18	70.77
Feb 18	76.29
Jan 18	85.48
Jan 18	83.88
Jan 18	98.44
Jan 18	97.54
Dec 17	97.59
Dec 17	101
Dec 17	98.24
Dec 17	98.44
Dec 17	104.17
Nov 17	96.33
Nov 17	99.5
Nov 17	91.26

No video analysis for this stock yet. Request one from our team.

News: OMER

defenseworld.net · 1 Sep 2026

BlackRock Inc. Invests $57.48 Million in Omeros Corporation $OMER

BlackRock Inc. purchased a new stake in Omeros Corporation (NASDAQ: OMER) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,044,633 shares of the biopharmaceutical company's stock, valued at approximately $57,484,000. BlackRock Inc. owned approximately 8.35% of Omeros at the end

zacks.com · 28 Aug 2026

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com · 25 Aug 2026

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

defenseworld.net · 15 Aug 2026

Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the

seekingalpha.com · 13 Aug 2026

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

marketbeat.com · 12 Aug 2026

Omeros Q2 Earnings Call Highlights

Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.

zacks.com · 12 Aug 2026

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to a loss of $0.53 per share a year ago.

businesswire.com · 12 Aug 2026

Omeros Corporation Reports Second Quarter 2026 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an incre.